Eli Wallace
About Eli Wallace
Eli Wallace serves as the Chief Executive Officer of Oncology R&D at BridgeBio, a position he has held since 2023. He earned his Ph.D. in Synthetic Organic Chemistry from Colorado State University and has extensive experience in the biopharmaceutical industry.
Work at BridgeBio
Eli Wallace currently serves as the Chief Executive Officer of Oncology R&D at BridgeBio, a position he has held since 2023. In this role, he oversees the development and implementation of research strategies focused on oncology. Prior to his current role, he worked at BridgeBio as Chief Scientific Officer In Residence from 2019 to 2023, contributing to various scientific initiatives and projects within the organization.
Education and Expertise
Eli Wallace earned his Ph.D. in Synthetic Organic Chemistry from Colorado State University, where he studied from 1990 to 1993. He also attended Northwestern University, further enhancing his academic background. His education provides a strong foundation for his expertise in medicinal chemistry and oncology research.
Background
Eli Wallace has a substantial background in the pharmaceutical industry, with over a decade of experience at Array BioPharma. He worked there as Director of Medicinal Chemistry from 2000 to 2011, where he was involved in the development of new therapeutic compounds. His career has been marked by a focus on advancing drug discovery and development processes.
Professional Experience
Before joining BridgeBio, Eli Wallace held significant roles that contributed to his expertise in oncology and medicinal chemistry. His tenure as Chief Scientific Officer In Residence at BridgeBio allowed him to guide research efforts and collaborate with various teams. His previous experience at Array BioPharma further solidified his capabilities in leading scientific projects.